‘Next Ozempic’ aims to offer a weight loss of 30% with less side effects

Researchers believe they can have the next and best version of Ozempic in process.

At the University of Tufts, scientists have developed a new medication that aims to increase weight loss while reducing nausea, muscle loss and weight recover associated with popular medicines of LPG-1.

The objective is that the medicine of “quadruple action” reaches the weight loss of up to 30% of up to 30%, coinciding with the effectiveness of bariatric surgery, which reduces the size of the stomach, according to a press release from the study.

Could GLP-1 weight loss medications like Ozempic become the ‘drug of everything’?

How the drug is different

Semaglutida medications, such as Ozempic and Wogovy, mimic GLP-1 natural hormone (peptide similar to glucagon-1), while pullzepatid receptors (such as Mounjaro and Zepbound) are aimed at GLP-1 receptors and GIP receptors (glucose-dependent insulinotropic polyginy).

The new Tufts medication is aimed at a combination of four hormones: LPG-1, GIP, glucagon (the counterpart to insulin) and the YY peptide, which reduces hunger, slows the emptying of the stomach and can promote fat burning.

“We build a single experimental peptide that works like four hormones at the same time, so we are not pressing a button too hard,” said News Digital, principal author, the main author, PHD, a researcher at the University of Tufts.

5 carbohydrates full of proteins that can help you lose weight and develop muscle, says the dietitian

“On the other hand, we are pushing four ‘attenuation switches’ to control appetite, blood sugar and energy use.”

Because LPG -1 and Pyy can contribute to nausea to higher doses, the researchers trusted GIP, which is known to facilitate nausea, to “balance things,” Densmore said.

“We build a single experimental peptide that works like four hormones at the same time, so we are not pressing a button too hard.”

“Beyond helping with fullness and glucose control, GIP signage has effects against nausea: it can even block nausea in preclinical models, so we prioritize it in the mixture,” he continued.

“By adding Pyy to the LPG -1/gip/glucagon trio, we hope to trust LPG -1 and glucagon less to boost weight loss, potentially reducing the possibilities of nausea (of LPG -1/Pyy) and high risk of blood sugar (glucagon) while maintaining the benefits.”

The medicine is still in the experimental/preclinical stage and has not yet been tested in human trials.

The development of the medication was published in the Journal of the American Chemical Society.

Doctors react

Dr. Brett Osborn, a Florida neurosurgeon and longevity expert, is a firm defender of GLP-1 medicines.

“There are many highly effective LPG-1 agonists just in front of us.”

“The only agent LGP-1 as Ozempic work for most people,” said Osborn, who did not participate in the TUFTS study, to News Digital. “Side effects are manageable when an experienced doctor supervises him.”

“We do not need more medications to treat the same chronic problem that has increasingly charged the world,” he added. “There are many highly effective LPG-1 agonists just in front of us.”

The greatest risks with LPG-1 is muscle loss and malnutrition below those unleashed, he said. To prevent this, the doctor emphasizes the need for adequate daily proteins and constant strength training.

To treat the “chronic” disease of obesity, Osborn recommends microdosis or intermittent LPG-1 dosage, combined with nutrition, progressive resistance training, hydration and sleep.

Mediterranean diet combined with other changes in lifestyle cuts the risk of diabetes

“Essentially, use the medication that works and combines with disciplined habits,” he advised. “I have used this approach for years, like many of my patients, with excellent long -term tolerance.”

Sue Decotiis, MD, a doctor of medical weight loss in New York City, said that controlling appetite, improving metabolism and increasing fat burning, while balancing blood sugar and insulin interactions, it is a “complex function.”

“The additional mechanisms offered by the new medications can help some, but not necessarily to most weight loss patients,” said Decotiis, who also did not participate in the study, News Digital.

“Even with new mechanisms added to medications for weight loss, individual patients will have varied responses in the amount of fat they lose.”

Click here to get the News application

He pointed out that their patients who take LPG-1 do not usually experience muscle and bone loss.

“Good care in medical weight loss should include the following patients with a body composition scale and monitoring, fiber and excellent hydration,” he said.

Limitations and future research

There were some limitations of the new medicine, the researchers recognized.

“The additional mechanisms offered by new medications can help some, but not necessarily to most weight loss patients.”

“This is a design investigation that shows the next generation potential and maybe even custom drugs,” Dinsmore told News Digital. “Our data come from cells based on cells, not animals or humans (still).”

“Choosing the safest and most effective balance of the four ways will require internal (living) and clinical trials.”

Click here to register in our health newsletter

Densmore advised people who use MPG -based medications with the guide of their clinician.

“This is not a medicine that I can get today,” he said about the new medicine. “Our work is a next generation concept that aims to improve results and reduce nausea by spreading work in four hormones instead of overloading one.”

It is estimated that obesity affects more than 40% of American adults and has been related to dozens of diseases, including type 2 diabetes, heart disease, stroke, sleep apnea, high blood pressure and various types of cancer.

For more health articles, visit www.Newsnews.com/health

“What drives us is the idea that we can design a single medicine to treat obesity and simultaneously mitigate the risk of developing a long list of health problems that affect society,” said the author of Co-Estudio Krishna Kumar, Robinson’s chemistry professor in Tufts.